Form 8-K Jade Biosciences, Inc. For: Jun 29
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/19/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Medifast launches Trilivy, replacing its Optavia brand
- Adobe has received a takeover approach by a Big Tech company - Betaville
Jade Biosciences licenses antibody program from Paragon Therapeutics
July 1, 2026 5:13 PM EDTJade Biosciences (NASDAQ: JBIO) entered into a license agreement with Paragon Therapeutics on June 29, 2026, securing worldwide exclusive rights to develop and commercialize certain monospecific antibodies targeting an undisclosed biological target across all human disease therapeutic areas.
Under the agreement, Jade Biosciences is obligated to pay Paragon up to $22.0 million in development and... More
